Close Menu

More articles about Reimbursement News

As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.   

The move follows the inclusion of Cologuard in the US Preventive Services Task Force's updated colorectal cancer screening recommendations.

The new coverage decisions follow updated recommendations from the US Preventive Services Task Force on colorectal cancer screening.

While undergoing parallel review for its FoundationOne test by the FDA and CMS, the firm will continue to work with its local MACs on reimbursement.

Revisions to the reimbursement catalog went into effect July 1, but stakeholders are quarreling about a pre-authorization requirement in court.

CMS gave labs an additional year to gear up for the implementation of the Protecting Access to Medicare Act of 2014 and clarified key programmatic definitions.

However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.

Some of the proposed payment rates for 2017 are low, but diagnostics firms will likely try to negotiate higher pricing during the 30-day comment period.

The colon cancer screening test is now covered in-network by the insurance company in Indiana, Ohio, Kentucky, Missouri, and Wisconsin.

Noridian said it has identified new data that will "significantly impact" its proposed policy on biomarker tests for guiding adjuvant chemotherapy decisions.

Immucor's PreciseType evaluates blood compatibility between donors and patients to help prevent mismatches that can cause potentially life-threatening reactions.

Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.

Pages